Equities analysts expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to announce $5.47 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with the highest sales estimate coming in at $6.20 million and the lowest estimate coming in at $4.90 million. The business is expected to announce its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that Aerie Pharmaceuticals will report full year sales of $23.46 million for the current financial year, with estimates ranging from $20.50 million to $25.45 million. For the next fiscal year, analysts expect that the business will post sales of $121.03 million per share, with estimates ranging from $100.90 million to $152.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, August 8th. The company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.16). The firm had revenue of $2.42 million during the quarter, compared to the consensus estimate of $1.16 million.

AERI has been the subject of several recent research reports. ValuEngine lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 26th. Mizuho reaffirmed a “buy” rating and set a $77.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, June 1st. BidaskClub lowered Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 7th. Canaccord Genuity set a $86.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 5th. Finally, Cantor Fitzgerald set a $86.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 8th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $82.67.

NASDAQ:AERI opened at $63.95 on Monday. The company has a market cap of $2.92 billion, a PE ratio of -18.98 and a beta of 0.86. Aerie Pharmaceuticals has a 52 week low of $47.05 and a 52 week high of $74.75. The company has a debt-to-equity ratio of 0.64, a current ratio of 10.27 and a quick ratio of 10.07.

In other news, CEO Vicente Anido, Jr. sold 150,000 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $62.28, for a total transaction of $9,342,000.00. Following the completion of the transaction, the chief executive officer now directly owns 176,320 shares in the company, valued at $10,981,209.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Casey C. Kopczynski sold 2,708 shares of the business’s stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $50.15, for a total value of $135,806.20. Following the transaction, the insider now owns 194,517 shares of the company’s stock, valued at $9,755,027.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 285,708 shares of company stock valued at $17,730,926. Insiders own 10.53% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY boosted its position in shares of Aerie Pharmaceuticals by 8.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 11,576 shares of the company’s stock worth $782,000 after buying an additional 877 shares during the period. Amalgamated Bank boosted its position in shares of Aerie Pharmaceuticals by 20.0% during the second quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock worth $368,000 after buying an additional 906 shares during the period. Xact Kapitalforvaltning AB boosted its position in shares of Aerie Pharmaceuticals by 21.0% during the second quarter. Xact Kapitalforvaltning AB now owns 5,751 shares of the company’s stock worth $388,000 after buying an additional 1,000 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of Aerie Pharmaceuticals by 7.0% during the second quarter. MetLife Investment Advisors LLC now owns 16,392 shares of the company’s stock worth $1,107,000 after buying an additional 1,066 shares during the period. Finally, Summit Trail Advisors LLC boosted its position in shares of Aerie Pharmaceuticals by 12.1% during the first quarter. Summit Trail Advisors LLC now owns 11,922 shares of the company’s stock worth $440,000 after buying an additional 1,283 shares during the period.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: How Short Selling Works

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.